Could immune cells slow ALS? new safety trial launches
Disease control
Recruiting now
This study tests whether a new treatment using a person's own regulatory T cells (Tregs) is safe for people with amyotrophic lateral sclerosis (ALS), a progressive nerve disease. Twelve adults aged 18 to 70 with ALS will receive the cell infusion and be monitored for side effects…
Phase: PHASE1 • Sponsor: Novabio Therapeutics • Aim: Disease control
Last updated May 04, 2026 16:22 UTC